Recently, the National academies of Sciences, Engineering and Medicine (NASEM) has recommended that people test their water and blood for per- and polyfluorinated substances (PFAS). This is a change from the past direction. The blood test places people into one of three categories based on the sum of seven pertinent PFAS. This sum then informs clinical care depending on the PFAS levels.
Traditionally, PFAS tests have been conducted with serum. This is true of the CDC studies and most academic cohorts. Only recently has technology developed to a point where both a volumetric sampling device and highly sensitive instrumentation can come together to assist the analytical challenge of a remote PFAS blood test. Equally important are the suite of isotopically labeled standards that are spiked into every sample to aid in quantitation. This approach is known as isotope dilution and it is considered the gold-standard of quantitation.
This talk aims to educate the viewer on this new approach for PFAS testing, and will be of particular interest to:
Health and safety officers
First responders
Academic researchers
Curious citizens
What you will learn
The vast majority of people have PFAS in their blood. It is a matter of what analytes and how much.
Attendees will learn about isotope dilution quantitation.
Attendees will learn about linear and branched PFAS isomers.
The basics of LC-MS/MS will be presented.
The talk will also include discussions on half-lives and bioaccumulation.
Speakers
VP of Innovation and Development, Specialty Services, Eurofins Environment North America
Andrew is the VP of Innovation and Development for Eurofins Environment Testing America for the Specialty Services division. He brings over 20 years of experience in the environmental laboratory industry with a focus on GC-HRMS and LC-MS/MS analyses. These approaches have focused on PCBs, dioxins, brominated flame-retardants, PFAS, emerging contaminants and human biomonitoring. He is among a handful of Eurofins scientists focused on techniques such as Non-target Analysis (NTA) via LC-QToF instrumentation. Recently, Andrew led the development for the PFAS Exposure fingerprick blood test. Andrew holds a Bachelor’s of Science in Microbiology with a concentration in Biochemistry from Cal Poly San Luis Obispo, CA, USA.
Moderator
Director Spooner Bioanalytical Solutions & Chair Patient Centric Sampling Interest Group
Neil is the Co-founder and Chair of the PCSIG. He is also the Founder of Spooner Bioanalytical Solutions, helping companies to integrate biological fluid microsampling, and patient centric sampling and analysis into workflows. He also works with organizations to develop technologies and introduce them to the market. Neil also assists organizations with their understanding of emerging trends in the pharmaceutical industry and bioanalysis. Neil is a Senior Visiting Research Fellow at the University of Hertfordshire, Editor in Chief of the journal, Bioanalysis and Chair of the Reid International Bioanalytical Forum. He has published over 70 peer reviewed manuscripts and delivered over 50 podium presentations.
IN ASSOCIATION WITH
OUR SPONSORS
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |
Alturas Analytics provides expert GLP & non-GLP LC-MS/MS and GC-MS/MS bioanalytical and PK/TK analysis services of small and large molecules in any matrix for discovery through Phase IV clinical trials.
Capitainer: Dried blood spots (DBS) is now quantitative with volumetric control through our microfluidic qDBS technology solution. Precision, accuracy, sample protection and ease of use both at sampling and in the lab are key features for us in all product development.
Charles River Laboratories are a leading drug discovery and development contract research organisation providing a broad spectrum of laboratory and data science support to the Clinical development industries. This includes bioanalytical chemistry, immunology, biomarker services, immunoassay, genomics, vaccine development and ADME services. With over 1000 dedicated laboratory colleagues across a global footprint and expertise in traditional and advanced modalities, Charles River Laboratories are well placed to leverage scale and scope to support Clinical programmes carried out anywhere in the world.
Genentech: Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit gene.com.
GSK: We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
MSD/Merck: We use the power of leading-edge science to save and improve lives around the world.
Q Solutions is a leading drug discovery and development laboratory services organization providing innovative solutions that encompass broad central laboratory and specialty biomarker services, including genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays, ADME and bioanalytical along with extensive offerings in antibody drug discovery, biomarker discovery, and decentralized clinical trial lab solutions. Through the Decentralized Clinical Trials group, Q Solutions is at the forefront of patient-centric sampling, offering a variety of self-collection methodologies and is validating multiple assays using micro-samples that are self-collected by study participants.
RedDrop Dx: Next generation blood sampling solutions.
Roche: Doing now what patients need next.
Takeda: We exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.
Tasso, is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time.
Veloxity Labs, is a CRO focused on LC-MS bioanalysis. Our company is employee owned and operated, and offers start-up times and turn-around times in days by maintaining 80% capacity.
Waters Corporation, a global leader in analytical instruments, consumables, and software, has pioneered innovations in chromatography, mass spectrometry, and thermal analysis serving the life sciences market for more than 60 years. Waters Corporation aligns with PCSIG's mission, supporting collaboration among diverse stakeholders to advance pharmaceutical medicines development and elevating healthcare outcomes and decision-making through analytical innovation and precision.
YourBio Health, makers of the TAP® device, was founded by Flagship Pioneering in 2007. TAP® is the world’s first push button collection device. Our technology allows a patient blood sample to be collected from any location without the pain of a fingerstick or need for traditional phlebotomy. We enable the decentralization of clinical trials and access to companies who offer wellness testing to consumers. Our patient-centric device is virtually painless, easy-to-use, and enables the collection of a blood specimen from any setting – clinical or in-home. We eliminate barriers to blood collection.
Comentarios